Navigation Links
Expert in IVD Software joins Visiopharm’s Board of Directors

Hørsholm, Denmark (PRWEB) January 03, 2013

Visiopharm a leader of Quantitative Digital Pathology solutions announced today that Dr. Henrik Stender will join Visiopharm’s Board of Directors.

Dr. Henrik Stender is co-founder of AdvanDx, where he was the Vice President of Research & Development. While with AdvanDx, he spearheaded the development of their PNA FISH technology; including clinical and regulatory activities for in-vitro diagnostic (IVD) use in Europe and in the United States. Today, as owner of Stender Diagnostics, Dr. Stender uses an ’IVD Factory’ concept to streamline the development process towards high quality products in compliance with quality system requirements (QSR) for regulatory approvals. Prior to AdvanDx, Henrik was at Applied Biosystems, Boston Probes, and Dako, where he built a deep and broad knowledge about medical devices and in-vitro diagnostics.

“I am very excited about joining Visiopharm, and see tremendous potential for their diagnostic solutions. Visiopharm already has a strong portfolio of algorithms for nuclear, membrane, and gene-probe analysis, which is currently under clinical validation and subsequent deployment at several hospitals. Still, there is a strong focus on developing and validating novel technology in software modules that truly addresses the demand for doing things better, faster, and cheaper. I believe this will be part of defining the future of Digital Pathology”, says Dr. Henrik Stender.

Michael Grunkin, CEO at Visiopharm stated “In-vitro diagnostics is a key business area for Visiopharm. We have an exciting development pipeline of IVD algorithms for the breast tumor panel, and this will set the foundation for the development of several other tumor panels. Dr. Stender is an important addition to our Board of Directors. His extensive knowledge and experience in the development of IVD products will be a great contribution to Visiopharm."

Johan Doré, CTO at Visiopharm adds, “We are seeing some interesting changes in Scandinavia these years, when it comes to adoption of Digital Pathology. We are collaborating with several hospitals in moving Digital Pathology into the clinic, and we have a very strong clinical network for validation though our close collaboration with the NordiQC. With his experience, Henrik is helping us optimizing our development work and clinical network in a regulatory context.”

Visiopharm recently introduced the HER2-CONNECT algorithm as their first CE-IVD cleared module and they are scheduled to launch a full CE-IVD tumor panel in 2013.

About Visiopharm

Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 350 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Nutrisystem Announces Latest Weight Loss Success Story: Long Beach Husband and Wife Drop a Combined Total of 46 Pounds; Plus, Expert Dieting Tips for Couples
2. Kettlebell Expert Lorna Kleidman Responds to the Rise in Fitness Parks throughout Major Cities
3. Fitness Expert Lorna Kleidman Comments on Article Concerning Weight Loss as a New Year’s Resolution
4. Whats Best for Kids Eye Health? Experts Give Insight
5. Boughs of Christmas Trees Hold Many Insects, Bug Expert Says
6. Its OK for Kids to Keep Believing in Santa, Expert Says
7. Stakeholder Communities in China and Korea – by Heartbeat Experts
8. Grief Expert Says "We Don't Die" and Offers Free Aid to Mourners
9. Aspergers, Autism Not Linked to Violence: Experts
10. Banning Vaccine Preservative Would Hurt Kids in Poor Nations: Experts
11. GLOBODOX (Enterprise Document Management Software) Launches Contest for Legal Experts to Define Technology Challenges Expected in 2013
Post Your Comments:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: